- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 54
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 172
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
- Interventions
- Arm 1
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 2
- States / cities
- Westport, Connecticut • Coral Springs, Florida
- Conditions
- Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- RGX-314
- Genetic
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 865 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- 4D-150 IVT, Aflibercept IVT
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Oxnard, California • Sacramento, California + 21 more
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- bevacizumab, ranibizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
- Interventions
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Westport, Connecticut
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- episcleral brachytherapy
- Radiation
- Lead sponsor
- Salutaris Medical Devices, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- ‘Aiea, Hawaii • Oak Forest, Illinois
- Conditions
- Macular Degeneration
- Interventions
- MSI-1256F (Squalamine Lactate)
- Drug
- Lead sponsor
- Genaera Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Plymouth Meeting, Pennsylvania
- Conditions
- Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- KSI-301
- Drug
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- EYC-0305
- Biological
- Lead sponsor
- Eyconis INC.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Modesto, California • Wake Forest, North Carolina + 4 more
- Conditions
- Exudative Macular Degeneration, Wet Age-related Macular Degeneration
- Interventions
- Doxycycline Hyclate, Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Submacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- Anti-VEGF, Hemorrhage displacement + Anti-VEGF
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- NG101 AAV gene therapy
- Genetic
- Lead sponsor
- Elisigen, Inc.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Risuteganib, Sham
- Drug · Other
- Lead sponsor
- Allegro Ophthalmics, LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 4 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- CLS-AX, Anti-VEGF
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Bakersfield, California • Mountain View, California + 8 more
- Conditions
- Wet Age Related Macular Degeneration, wAMD
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more
- Conditions
- Macular Degeneration
- Interventions
- NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
- Drug
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
- Conditions
- Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
- Interventions
- LFG316, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, ranibizumab, E10030 sham intravitreal injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 627 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Fresno, California • La Jolla, California + 43 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more